380 related articles for article (PubMed ID: 26156021)
1. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
2. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
[TBL] [Abstract][Full Text] [Related]
3. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
[TBL] [Abstract][Full Text] [Related]
5. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang TT; Wang RM; Yang Z; Chen GB
Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
11. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
[TBL] [Abstract][Full Text] [Related]
15. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
Liu L; Zhang Y; Wei J; Chen Z; Yu J
J Cancer; 2019; 10(4):799-809. PubMed ID: 30854085
[No Abstract] [Full Text] [Related]
16. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
Ding F; Liu B; Wang Y
J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
20. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]